Comparative Pharmacology
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus SEMPREX D.
CLEMASTINE FUMARATE vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
1.34 mg orally twice daily; max 8.04 mg/day
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination